The scientific rationale for optimizing nutritional support in cancer

European Journal of Gastroenterology and Hepatology

Volumn 19, Issue 5, 2007, Pages 371-377

  Skipworth, Richard J E ^a   Fearon, Kenneth C H ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Anorexia; Cachexia; Cancer; Muscle; Nutrition; Proinflammatory cytokine

Indexed keywords

GROWTH HORMONE; MYOSTATIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN BINDING PROTEIN 1; TRANSCRIPTION FACTOR FOXO; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN PROTEIN LIGASE E3;

ADVANCED CANCER; ANOREXIA; BLADDER CANCER; BREAST CARCINOMA; CACHEXIA; CANCER PATIENT; CLINICAL RESEARCH; COLON CARCINOGENESIS; DIET RESTRICTION; ENERGY BALANCE; ENERGY CONSUMPTION; ENERGY EXPENDITURE; HUMAN; MUSCLE ATROPHY; MUSCLE MASS; NUTRITIONAL HEALTH; NUTRITIONAL SUPPORT; OVERNUTRITION; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN METABOLISM; REVIEW; TRANSITIONAL CELL CARCINOMA; TUMOR GROWTH; WASTING SYNDROME; WEIGHT REDUCTION;

CACHEXIA; ENERGY METABOLISM; HUMANS; NEOPLASMS; NUTRITIONAL SUPPORT; PROTEINS; TREATMENT FAILURE;

EID: 34247163043     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3280bdbf87     Document Type: Review

References (71)

1. Nixon DW, Lawson DH, Kutner M, Ansley J, Schwarz M, Heymsfield S, et al. Hyperalimentation of the cancer patient with protein-calorie undernutrition. Cancer Res 1981; 41:2038-2045.
2. Kritchevsky D. The effect of over- and undernutrition on cancer. Eur J Cancer Prev 1995; 4:445-451.
3. Hursting SD, Perkins SN, Brown CC, Haines DC, Phang JM. Calorie restriction induces a p53-independent delay of spontaneous carcinogenesis in p53-deficient and wild-type mice. Cancer Res 1997; 57:2843-2846.
4. Kari FW, Dunn SE, French JE, Barrett JC. Roles for insulin-like growth factor-1 in mediating the anti-carcinogenic effects of caloric restriction. J Nutr Health Aging 1999; 3:92-101.
5. Mukherjee P, Sotnikov AV, Mangian HJ, Zhou JR, Visek WJ, Clinton SK. Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression. J Natl Cancer Inst 1999; 91:512-523.
6. Dunn SE, Kari FW, French J, Leininger JR, Travlos G, Wilson R, et al. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res 1997; 57:4667-4672.
7. Oh JS, Kucab JE, Bushel PR, Martin K, Bennett L, Collins J, et al. Insulin-like growth factor-1 inscribes a gene expression profile for angiogenic factors and cancer progression in breast epithelial cells. Neoplasia 2002; 4:204-217.
8. Kritchevsky D. Caloric restriction and experimental carcinogenesis. Hybrid Hybridomics 2002; 21:147-151.
9. McNurlan MA, Heys SD, Park KG, Broom J, Brown DS, Eremin O, et al. Tumour and host tissue responses to branched-chain amino acid supplementation of patients with cancer. Clin Sci (Lond) 1994; 86:339-345.
10. Carrascosa JM, Martinez P, Nunez dC I. Nitrogen movement between host and tumor in mice inoculated with Ehrlich ascitic tumor cells. Cancer Res 1984; 44:3831-3835.
11. Hyltander A, Drott C, Korner U, Sandstrom R, Lundholm K. Elevated energy expenditure in cancer patients with solid tumours. Eur J Cancer 1991; 27:9-15.
12. Nixon DW, Kutner M, Heymsfield S, Foltz AT, Carty C, Seitz S, et al. Resting energy expenditure in lung and colon cancer. Metabolism 1988; 37:1059-1064.
13. Knox LS, Crosby LO, Feurer ID, Buzby GP, Miller CL, Mullen JL. Energy expenditure in malnourished cancer patients. Ann Surg 1983; 197:152-162.
14. Fredrix EW, Soeters PB, Wouters EF, Deerenberg IM, Von Meyenfeldt MF, Saris WH. Effect of different tumor types on resting energy expenditure. Cancer Res 1991; 51:6138-6141.
15. Falconer JS, Fearon KC, Plester CE, Ross JA, Carter DC. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 1994; 219:325-331.
16. Fredrix EW, Soeters PB, Rouflart MJ, Von Meyenfeldt MF, Saris WH. Resting energy expenditure in patients with newly detected gastric and colorectal cancers. Am J Clin Nutr 1991; 53:1318-1322.
17. Moses AW, Slater C, Preston T, Barber MD, Fearon KC. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer 2004; 90:996-1002.
18. McMillan DC, Preston T, Fearon KC, Burns HJ, Slater C, Shenkin A. Protein synthesis in cancer patients with inflammatory response: investigations with [15N]glycine. Nutrition 1994; 10:232-240.
19. Fearon KC, Preston T. Body composition in cancer cachexia. Infusionstherapie 1990; 17 (Suppl 3):63-66.
20. Khal J, Hine AV, Fearon KC, Dejong CH, Tisdale MJ. Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. Int J Biochem Cell Biol 2005; 37:2196-2206.
21. Tisdale MJ. Loss of skeletal muscle in cancer: biochemical mechanisms. Front Biosci 2001; 6:D164-D174.
22. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001; 294:1704-1708.
23. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci U S A 2001; 98:14440-14445.
24. Acharyya S, Ladner KJ, Nelsen LL, Damrauer J, Reiser PJ, Swoap S, et al. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest 2004; 114:370-378.
25. Cai D, Frantz JD, Tawa NE Jr, Melendez PA, Oh BC, Lidov HG, et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 2004; 119:285-298.
26. Madrid LV, Wang CY, Guttridge DC, Schottelius AJ, Baldwin AS Jr, Mayo MW. Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB. Mol Cell Biol 2000; 20:1626-1638.
27. Guttridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin AS Jr. NF-kappaBinduced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000; 289:2363-2366.
28. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004; 117:399-412.
29. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophyinduced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004; 14:395-403.
30. Acharyya S, Butchbach ME, Sahenk Z,Wang H, Saji M, Carathers M, et al. Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell 2005; 8:421-432.
31. Todorov PT, Deacon M, Tisdale MJ. Structural analysis of a tumor-produced sulfated glycoprotein capable of initiating muscle protein degradation. J Biol Chem 1997; 272:12279-12288.
32. Smith HJ, Tisdale MJ. Induction of apoptosis by a cachectic-factor in murine myotubes and inhibition by eicosapentaenoic acid. Apoptosis 2003; 8:161-169.
33. Cariuk P, Lorite MJ, Todorov PT, Field WN, Wigmore SJ, Tisdale MJ. Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients. Br J Cancer 1997; 76:606-613.
34. Wigmore SJ, Todorov PT, Barber MD, Ross JA, Tisdale MJ, Fearon KC. Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor. Br J Surg 2000; 87:53-58.
35. Preston T, Slater C, McMillan DC, Falconer JS, Shenkin A, Fearon KC. Fibrinogen synthesis is elevated in fasting cancer patients with an acute phase response. J Nutr 1998; 128:1355-1360.
36. Wigmore SJ, Fearon KC, Sangster K, Maingay JP, Garden OJ, Ross JA. Cytokine regulation of constitutive production of interleukin-8 and -6 by human pancreatic cancer cell lines and serum cytokine concentrations in patients with pancreatic cancer. Int J Oncol 2002; 21:881-886.
37. Wigmore SJ, Fearon KC, Maingay JP, Garden OJ, Ross JA. Effect of interleukin-2 on peripheral blood mononuclear cell cytokine production and the hepatic acute phase protein response. Clin Immunol 2002; 104:174-182.
38. O'Riordain MG, Falconer JS, Maingay J, Fearon KC, Ross JA. Peripheral blood cells from weight-losing cancer patients control the hepatic acute phase response by a primarily interleukin-6 dependent mechanism. Int J Oncol 1999; 15:823-827.
39. Falconer JS, Fearon KC, Ross JA, Elton R, Wigmore SJ, Garden OJ, et al. Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 1995; 75:2077-2082.
40. Wigmore SJ, McMahon AJ, Sturgeon CM, Fearon KC. Acute-phase protein response, survival and tumour recurrence in patients with colorectal cancer. Br J Surg 2001; 88:255-260.
41. Staal-van den Brekel AJ, Dentener MA, Schols AM, Buurman WA, Wouters EF. Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J Clin Oncol 1995; 13:2600-2605.
42. Tartour E, Dorval T, Mosseri V, Deneux L, Mathiot C, Brailly H, et al. Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer 1994; 69:911-913.
43. Merlini G, Perfetti V, Gobbi PG, Quaglini S, Franciotta DM, Marinone G, et al. Acute phase proteins and prognosis in multiple myeloma. Br J Haematol 1993; 83:595-601.
44. Zielinski CC, Preis P, Aiginger P, Eibl MM. Acute-phase-proteins and parameters of humoral immunity in patients with advanced Hodgkin's disease. J Cancer Res Clin Oncol 1985; 110:65-70.
45. Kodama J, Miyagi Y, Seki N, Tokumo K, Yoshinouchi M, Kobashi Y, et al. Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1999; 82:107-110.
46. Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992; 52:3317-3322.
47. Barber MD, Fearon KC. Tolerance and incorporation of a high-dose eicosapentaenoic acid diester emulsion by patients with pancreatic cancer cachexia. Lipids 2001; 36:347-351.
48. McMillan DC, Preston T,Watson WS, Simpson JM, Fearon KC, Shenkin A, et al. Relationship between weight loss, reduction of body cell mass and inflammatory response in patients with cancer. Br J Surg 1994; 81:1011-1014.
49. Wigmore SJ, Plester CE, Ross JA, Fearon KC. Contribution of anorexia and hypermetabolism to weight loss in anicteric patients with pancreatic cancer. Br J Surg 1997; 84:196-197.
50. Deans C, Wigmore S, Paterson-Brown S, Black J, Ross J, Fearon KC. Serum parathyroid hormone-related peptide is associated with systemic inflammation and adverse prognosis in gastroesophageal carcinoma. Cancer 2005; 103:1810-1818.
51. Barber MD, Powell JJ, Lynch SF, Fearon KC, Ross JA. A polymorphism of the interleukin-1 beta gene influences survival in pancreatic cancer. Br J Cancer 2000; 83:1443-1447.
52. Ruzzo A, Graziano F, Pizzagalli F, Santini D, Battistelli V, Panunzi S, et al. Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in Helicobacter pylori-negative gastric cancer of intestinal and diffuse histotype. Ann Oncol 2005; 16:887-892.
53. Halma MA, Wheelhouse NM, Barber MD, Powell JJ, Fearon KC, Ross JA. Interferon-gamma polymorphisms correlate with duration of survival in pancreatic cancer. Hum Immunol 2004; 65:1405-1408.
54. Sheen-Chen SM, Chen WJ, Eng HL, Chou FF. Serum concentration of tumor necrosis factor in patients with breast cancer. Breast Cancer Res Treat 1997; 43:211-215.
55. Busquets S, Figueras MT, Meijsing S, Carbo N, Quinn LS, Almendro V, et al. Interleukin-15 decreases proteolysis in skeletal muscle: a direct effect. Int J Mol Med 2005; 16:471-476.
56. Barber MD, McMillan DC,Wallace AM, Ross JA, Preston T, Fearon KC. The response of leptin, interleukin-6 and fat oxidation to feeding in weight-losing patients with pancreatic cancer. Br J Cancer 2004; 90:1129-1132.
57. Heber D, Byerley LO, Tchekmedyian NS. Hormonal and metabolic abnormalities in the malnourished cancer patient: effects on host-tumor interaction. JPEN J Parenter Enteral Nutr 1992; 16 (6 Suppl):60S-64S.
58. Chlebowski RT, Heber D. Hypogonadism in male patients with metastatic cancer prior to chemotherapy. Cancer Res 1982; 42:2495-2498.
59. Moretti C, Frajese GV, Guccione L,Wannenes F, De Martino MU, Fabbri A, et al. Androgens and body composition in the aging male. J Endocrinol Invest 2005; 28 (3 Suppl):56-64.
60. Matsakas A, Diel P. The growth factor myostatin, a key regulator in skeletal muscle growth and homeostasis. Int J Sports Med 2005; 26:83-89.
61. Grobet L, Martin LJ, Poncelet D, Pirottin D, Brouwers B, Riquet J, et al. A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nat Genet 1997; 17:71-74.
62. McCroskery S, Thomas M, Platt L, Hennebry A, Nishimura T, McLeay L, et al. Improved muscle healing through enhanced regeneration and reduced fibrosis in myostatin-null mice. J Cell Sci 2005; 118 (Pt 15):3531-3541.
63. Catipovic B. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 2004; 351:1030-1031.
64. Gibney ER. Energy expenditure in disease: time to revisit? Proc Nutr Soc 2000; 59:199-207.
65. Franssen FM, Wouters EF, Schols AM. The contribution of starvation, deconditioning and ageing to the observed alterations in peripheral skeletal muscle in chronic organ diseases. Clin Nutr 2002; 21:1-14.
66. Mollinger LA, Spurr GB, el Ghatit AZ, Barboriak JJ, Rooney CB, Davidoff DD, et al. Daily energy expenditure and basal metabolic rates of patients with spinal cord injury. Arch Phys Med Rehabil 1985; 66:420-426.
67. Stallings VA, Zemel BS, Davies JC, Cronk CE, Charney EB. Energy expenditure of children and adolescents with severe disabilities: a cerebral palsy model. Am J Clin Nutr 1996; 64:627-634.
68. Biolo G, Ciocchi B, Lebenstedt M, Barazzoni R, Zanetti M, Platen P, et al. Short-term bed rest impairs amino acid-induced protein anabolism in humans. J Physiol 2004; 558 (Pt 2):381-388.
69. Laviano A, Meguid MM, Rossi-Fanelli F. Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies. Lancet Oncol 2003; 4:686-694.
70. Wigmore SJ, Barber MD, Ross JA, Tisdale MJ, Fearon KC. Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer 2000; 36:177-184.
71. Lundholm K, Daneryd P, Bosaeus I, Korner U, Lindholm E. Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: effects on survival, metabolism, and function. Cancer 2004; 100:1967-1977.